???These new data indicate that HDAC3 inhibitors should be further evaluated for use in a variety of disorders in which the acquisition or extinction of long-term memory is a factor,??? suggests Walter C. Herlihy, Repligen president and CEO. ???We intend to continue to investigate the potentialof our selective HDAC3 inhibitors in a variety of disease models.???